gadobenate dimeglumine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
diagnostic agents, gadolinium derivatives 4471 127000-20-8

Description:

MoleculeDescription

Synonyms:

  • multihance
  • gadobenate dimeglumine
  • Molecular weight: 1058.16
  • Formula: C36H62GdN5O21
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Nov. 23, 2004 FDA BRACCO

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Nephrogenic systemic fibrosis 556.70 52.62 120 4954 4202 50595848
Hypersensitivity 362.12 52.62 239 4835 214922 50385128
Contrast media reaction 298.24 52.62 56 5018 951 50599099
Urticaria 287.84 52.62 172 4902 129389 50470661
Skin hypertrophy 251.26 52.62 59 5015 3036 50597014
Anaphylactic reaction 236.79 52.62 113 4961 53942 50546108
Skin induration 223.26 52.62 53 5021 2858 50597192
Anaphylactoid reaction 199.91 52.62 50 5024 3356 50596694
Skin tightness 199.86 52.62 51 5023 3712 50596338
Sneezing 174.43 52.62 62 5012 13982 50586068
Pruritus 151.88 52.62 163 4911 283405 50316645
Vomiting 149.20 52.62 205 4869 460553 50139497
Skin fibrosis 139.93 52.62 29 5045 830 50599220
Erythema 137.40 52.62 115 4959 146299 50453751
Fibrosis 124.20 52.62 35 5039 3712 50596338
Nausea 120.63 52.62 235 4839 705163 49894887
Throat tightness 89.28 52.62 43 5031 20804 50579246
Throat irritation 85.05 52.62 47 5027 30192 50569858
Feeling hot 83.86 52.62 51 5023 39151 50560899
Skin hyperpigmentation 75.86 52.62 26 5048 5250 50594800
Dyspnoea 74.93 52.62 167 4907 547441 50052609
Gadolinium deposition disease 71.28 52.62 11 5063 51 50599999
Joint contracture 70.94 52.62 19 5055 1665 50598385
Joint range of motion decreased 69.75 52.62 35 5039 18477 50581573
Foaming at mouth 68.75 52.62 17 5057 1085 50598965
Peau d'orange 68.54 52.62 12 5062 134 50599916
Emotional distress 68.34 52.62 40 5034 28623 50571427
Scar 68.21 52.62 30 5044 11788 50588262
Anaphylactic shock 66.94 52.62 35 5039 20120 50579930
Contrast media allergy 62.94 52.62 18 5056 2009 50598041
Anhedonia 57.64 52.62 25 5049 9499 50590551
Drug ineffective 56.07 52.62 8 5066 819325 49780725
Skin discolouration 56.00 52.62 37 5037 32720 50567330

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Nephrogenic systemic fibrosis 379.50 56.07 87 3033 3855 29567552
Hypersensitivity 290.55 56.07 131 2989 52772 29518635
Urticaria 172.59 56.07 93 3027 54567 29516840
Vomiting 172.13 56.07 156 2964 212104 29359303
Anaphylactic reaction 165.96 56.07 73 3047 27500 29543907
Skin induration 158.79 56.07 38 3082 2016 29569391
Skin hypertrophy 157.90 56.07 39 3081 2364 29569043
Nausea 157.47 56.07 171 2949 289084 29282323
Sneezing 156.90 56.07 44 3076 4370 29567037
Anaphylactoid reaction 150.44 56.07 36 3084 1909 29569498
Skin tightness 144.93 56.07 35 3085 1929 29569478
Contrast media reaction 140.39 56.07 29 3091 776 29570631
Joint contracture 107.15 56.07 27 3093 1773 29569634
Fibrosis 95.23 56.07 26 3094 2333 29569074
Joint range of motion decreased 94.05 56.07 32 3088 6022 29565385
Skin fibrosis 90.20 56.07 21 3099 986 29570421
Scar 85.57 56.07 29 3091 5390 29566017
Anaphylactic shock 82.32 56.07 36 3084 13300 29558107
Pruritus 80.80 56.07 79 3041 116770 29454637
Extremity contracture 74.97 56.07 17 3103 709 29570698
Deformity 72.65 56.07 19 3101 1445 29569962
Emotional distress 56.17 56.07 28 3092 13867 29557540

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Nephrogenic systemic fibrosis 576.39 65.25 131 6441 5761 64486399
Hypersensitivity 574.30 65.25 313 6259 196139 64296021
Anaphylactic reaction 378.19 65.25 169 6403 68495 64423665
Urticaria 361.99 65.25 210 6362 147107 64345053
Contrast media reaction 340.27 65.25 69 6503 1743 64490417
Anaphylactoid reaction 314.48 65.25 77 6495 4661 64487499
Skin hypertrophy 312.81 65.25 76 6496 4453 64487707
Skin induration 272.74 65.25 67 6505 4108 64488052
Sneezing 269.34 65.25 88 6484 15163 64476997
Skin tightness 266.17 65.25 68 6504 4893 64487267
Vomiting 244.84 65.25 289 6283 550828 63941332
Nausea 220.84 65.25 329 6243 785471 63706689
Pruritus 209.08 65.25 204 6368 312196 64179964
Skin fibrosis 172.92 65.25 38 6534 1421 64490739
Erythema 153.34 65.25 137 6435 186933 64305227
Fibrosis 137.37 65.25 40 6532 4688 64487472
Anaphylactic shock 133.33 65.25 64 6508 30264 64461896
Joint contracture 125.38 65.25 32 6540 2287 64489873
Joint range of motion decreased 117.07 65.25 51 6521 19292 64472868
Scar 103.40 65.25 42 6530 13356 64478804
Skin hyperpigmentation 96.47 65.25 33 6539 6518 64485642
Throat tightness 93.13 65.25 46 6526 23114 64469046
Gadolinium deposition disease 90.48 65.25 14 6558 65 64492095
Throat irritation 86.20 65.25 49 6523 32662 64459498
Feeling hot 85.69 65.25 55 6517 45608 64446552
Contrast media allergy 84.39 65.25 23 6549 2118 64490042
Peau d'orange 83.74 65.25 16 6556 293 64491867
Contrast media deposition 74.83 65.25 12 6560 73 64492087
Dyspnoea 70.36 65.25 195 6377 718479 63773681
Emotional distress 66.59 65.25 43 6529 35995 64456165

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
MeSH PA D003287 Contrast Media
MeSH PA D064907 Diagnostic Uses of Chemicals

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
4032768 VUID
N0000188993 NUI
4032768 VANDF
CHEMBL1200571 ChEMBL_ID
C064572 MESH_SUPPLEMENTAL_RECORD_UI
3Q6PPC19PO UNII
24838350 PUBCHEM_CID
68173 RXNORM
19178 MMSL
64278 MMSL
64293 MMSL
d05428 MMSL
007717 NDDF
414308003 SNOMEDCT_US
C0209453 UMLSCUI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
MultiHance HUMAN PRESCRIPTION DRUG LABEL 1 0270-5164 INJECTION, SOLUTION 529 mg INTRAVENOUS NDA 28 sections
MultiHance HUMAN PRESCRIPTION DRUG LABEL 1 0270-5264 INJECTION, SOLUTION 529 mg INTRAVENOUS NDA 27 sections